Skip to main content
Clinical Trials/EUCTR2015-005234-21-DK
EUCTR2015-005234-21-DKActive, not recruitingPhase 1

A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache

Eli Lilly and Company0 sites324 target enrollmentStarted: July 27, 2016Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
324

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Participants who participated in and completed either Study CGAL or Study CGAM.
  • •Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 304
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

  • •Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of Study CGAL or Study CGAM).
  • •Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF) (with the exception of Study CGAL or Study CGAM).
  • •A history of migraine variants that could implicate or could be confused with ischemia.
  • •Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.
  • •A history or presence of other medical illness that indicates a medical problem that would preclude study participation.
  • •Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.
  • •Women who are pregnant or nursing.

Investigators

Similar Trials